doi,title,authors,publish_type,is_most_recent_version,url_most_most_version,main_comparison_of_review,main_comparison_population,main_comparison_setting,main_comparison_comparsion_type,background,objectives,search_methods,selection_criteria,data_coll_analysis,main_results,conclusions,summaryTable_count,GRADE_somewhere_in_the_text,is_paywalled,warning,id_measure,Outcomes,relative_effect_95CI,n_participants_studies,GRADE,Comments,effect_statistic,n_participants,n_studies,CI_lower,CI_upper,effect_size
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,1,"Pneumonia, community acquired, at least 1 episode Follow‐up: range 6 to 36 months",OR 0.59 (0.41 to 0.85),1372 (6 RCTs),⊕⊕⊕⊝ Moderatea,Study limitations with lack of participant blinding and no use of placebo in 3 studies. NNTB to prevent 1 episode of CAP = 19 (95% CI 13 to 52),OR,1372,1372,0.41,0.85,OR 0.59
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,2,"Pneumococcal pneumonia, at least 1 episode Follow‐up: range 6 to 36 months",OR 0.26 (0.05 to 1.31),1158 (3 RCTs),"⊕⊕⊝⊝ Lowb,c",Very few confirmed episodes of pneumococcal pneumonia. Rate of pneumococcal CAP to total CAP from 2008 to 2013 varied from 17.1% to 37.3% of cases (Rodrigo 2015).,OR,1158,1158,0.05,1.31,OR 0.26
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,3,Death from cardiorespiratory causes Follow‐up: range 24 to 48 months,OR 1.07 (0.69 to 1.66),888 (3 RCTs),⊕⊕⊕⊝ Moderated,,OR,888,888,0.69,1.66,OR 1.07
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,4,Death from all causes Follow‐up: range 12 to 48 months,OR 1.00 (0.72 to 1.40),1053 (5 RCTs),⊕⊕⊕⊝ Moderated,,OR,1053,1053,0.72,1.40,OR 1.00
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,5,"Hospital admission: any cause, at least 1 episode Follow‐up: range 6 to 12 months",OR 0.74 (0.32 to 1.74),391 (3 RCTs),⊕⊕⊕⊝ Moderated,,OR,391,391,0.32,1.74,OR 0.74
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,6,COPD exacerbation: at least 1 episode Follow‐up: range 6 to 24 months,OR 0.60 (0.39 to 0.93),446 (4 RCTs),⊕⊕⊕⊝ Moderatea,Study limitations with lack of or unclear participant blinding in 3 studies. NNTB = 8 (95% CI 5 to 58); see Figure 1,OR,446,446,0.39,0.93,OR 0.60
https://doi.org/10.1002/14651858.CD001390.pub4,Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease,"Julia AE Walters, Joanne Ngie Qing Tang, Phillippa Poole, Richard Wood‐Baker",Review - Intervention,TRUE,NA,Is pneumococcal vaccination effective in preventing pneumonia in chronic obstructive pulmonary disease?,patients with COPD,community,control,"People with chronic obstructive pulmonary disease (COPD) are at increased risk of pneumococcal disease, especially pneumonia, as well as acute exacerbations with associated morbidity and healthcare costs.",To determine the efficacy of injectable pneumococcal vaccination for preventing pneumonia in persons with COPD.,"We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.","We searched the Cochrane Airways COPD Trials Register and the databases CENTRAL, MEDLINE and Embase, using prespecified terms. Searches are current to November 2016.  Selection criteria We included randomised controlled trials (RCT) comparing injectable pneumococcal polysaccharide vaccine (PPV) or pneumococcal conjugated vaccine (PCV) versus a control or alternative vaccine type in people with COPD.","We used standard Cochrane methodological procedures. For meta‐analyses, we subgrouped studies by vaccine type.","For this update, we added five studies (606 participants), meaning that the review now includes a total of 12 RCTs involving 2171 participants with COPD. Average age of participants was 66 years, male participants accounted for 67% and mean forced expiratory volume in one second (FEV1) was 1.2 L (five studies), 54% predicted (four studies). We assessed risks of selection, attrition and reporting bias as low, and risks of performance and detection bias as moderate.  Compared with control, the vaccine group had a lower likelihood of developing community‐acquired pneumonia (CAP) (odds ratio (OR) 0.59 , 95% confidence interval (CI) 0.41 to 0.85; six studies, n = 1372; GRADE: moderate), but findings did not differ specifically for pneumococcal pneumonia (Peto OR 0.26, 95% CI 0.05 to 1.31; three studies, n = 1158; GRADE: low). The number needed to treat for an additional beneficial outcome (NNTB) (preventing one episode of CAP) was 19 (95% CI 13 to 52). Mortality from cardiorespiratory causes did not differ between vaccine and control groups (OR 1.07, 95% CI 0.69 to 1.66; three studies, n = 888; GRADE: moderate), nor did all‐cause mortality differ (OR 1.00, 95% CI 0.72 to 1.40; five studies, n = 1053; GRADE: moderate). The likelihood of hospital admission for any cause, or for cardiorespiratory causes, did not differ between vaccine and control groups. Vaccination significantly reduced the likelihood of a COPD exacerbation (OR 0.60, 95% CI 0.39 to 0.93; four studies, n = 446; GRADE: moderate). The NNTB to prevent a patient from experiencing an acute exacerbation was 8 (95% CI 5 to 58). Only one study (n = 181) compared the efficacy of different vaccine types ‐ 23‐valent PPV versus 7‐valent PCV ‐ and reported no differences for CAP, all‐cause mortality, hospital admission or likelihood of a COPD exacerbation, but investigators described a greater likelihood of some mild adverse effects of vaccination with PPV‐23.","Injectable polyvalent pneumococcal vaccination provides significant protection against community‐acquired pneumonia, although no evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate‐quality evidence suggests the benefits of pneumococcal vaccination in people with COPD. Evidence was insufficient for comparison of different pneumococcal vaccine types.",1,TRUE,FALSE,NO warnings,7,Lung function: FEV1 (L) Follow‐up: 12 months,‐,142 (1 RCT),"⊕⊕⊝⊝ Lowd,e",No difference in lung function seen at 3 or 24 months in 1 study,OR,142,142,NA,NA,NA
